---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-031780"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:40:06.855078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Humacyte reports preliminary FY2025 revenue $2M, 61 Symvess units; suspends ATM

## Summary
- Preliminary FY2025: cash $50.9M, total revenue $2.0M (product $1.4M), 61 Symvess unit sales.
- Received $1.48M minimum purchase commitment from KSA entity for Symvess; exclusive negotiations through July 2026.
- Filed Marketing Authorization Application in Israel for Symvess in vascular trauma; also pursuing hospital-by-hospital access.
- Suspended $60M ATM program effective March 19, 2026; no further sales unless new prospectus filed.
- Risk factors updated; accumulated deficit $702M as of Sep 2025, company expects need for additional funding.

## SEC filing metadata
- accession: 0001104659-26-031780
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926031780/0001104659-26-031780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926031780/tm269106d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-031780
- JSON: https://secwatch.observer/filing/0001104659-26-031780.json
- Plain text: https://secwatch.observer/filing/0001104659-26-031780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.